Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Familial Mediterranean Fever and Related Disorders: Genetics and Disease CharacteristicsRecruiting
NCT00001373N/AUpdated Aug 17, 2026
Sponsor: National Human Genome Research Institute (NHGRI)
Familial Mediterranean Fever (FMF) · Autoinflammation · Periodic Fever · Fever
United States
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)Recruiting
NCT07176689Phase 4Updated Aug 17, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Desmoid Tumor · Aggressive Fibromatosis
Belgium, Germany, Italy, Netherlands, Spain +1 more
Met Non Small Cell Cancer Registry (MOMENT)Recruiting
NCT05376891N/AUpdated Aug 17, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Cancer
United States, Austria, Belgium, Canada, Czechia +9 more
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)Recruiting
NCT07431827Phase 3Updated Aug 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Argentina, Australia, Brazil, Canada, Chile +10 more
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell LymphomaRecruiting
NCT07673367Phase 2Updated Aug 17, 2026
Sponsor: Vanderbilt-Ingram Cancer Center
Recurrent Mantle Cell Lymphoma · Refractory Mantle Cell Lymphoma
United States
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompleted
NCT03654833Phase 2Updated Aug 17, 2026
Sponsor: University of Leicester
Mesothelioma, Malignant
United Kingdom
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsRecruiting
NCT07360314Phase 1Updated Aug 17, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumors
United States, Canada, Japan, Spain
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)Active Not Recruiting
NCT07242469Phase 1Updated Aug 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
United States
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)Recruiting
NCT07348237Phase 1Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Chronic Kidney Failure · End-Stage Renal Disease · Renal Impairment
United States
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)Recruiting
NCT07519772Phase 1, Phase 2Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse
United States, Argentina, Australia, Canada, China +7 more
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)Recruiting
NCT07044297Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV) · HIV Pre-Exposure Prophylaxis
United States, Argentina, Brazil, Chile, Colombia +11 more
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)Recruiting
NCT07570173Phase 2, Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia
Denmark, Greece, Israel, Italy, Japan +2 more
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)Active Not Recruiting
NCT03742895Phase 2Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced Solid Neoplasms
United States, Argentina, Australia, Canada, Colombia +16 more
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)Recruiting
NCT07489495Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
United States, Argentina, Australia, Brazil, Chile +13 more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Recruiting
NCT06312176Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +35 more
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)Recruiting
NCT06655883Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Insomnia
United States
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseRecruiting
NCT07332481Phase 3Updated Aug 14, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Systemic Lupus Erythematosus (SLE) · Cutaneous Lupus Erythematosus (CLE)
United States, Japan, Switzerland
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)Recruiting
NCT06843447Phase 1, Phase 2Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer Recurrent
United States, Canada, Israel, Spain, United Kingdom
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerRecruiting
NCT05231122Phase 2Updated Aug 14, 2026
Sponsor: Roswell Park Cancer Institute
Ovarian Clear Cell Adenocarcinoma · Platinum-Sensitive Ovarian Carcinoma · Recurrent Endometrial Serous Adenocarcinoma · Recurrent Fallopian Tube Carcinoma
United States
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Active Not Recruiting
NCT06074588Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Australia, Brazil, Canada, Chile +20 more
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)Recruiting
NCT06667700Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Coronavirus Disease (COVID-19)
United States, Argentina, Brazil, Bulgaria, Colombia +19 more
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)Recruiting
NCT07071623Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV) · HIV Pre-Exposure Prophylaxis
Kenya, South Africa, Uganda
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)Recruiting
NCT07549412Phase 3Updated Aug 14, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Metastatic Colorectal Cancer
United States, Australia, Canada, China, Japan +2 more
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Recruiting
NCT07060807Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Brazil, Canada +21 more
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid TumorsTerminated
NCT05083481Phase 1Updated Aug 14, 2026
Sponsor: Astellas Pharma Global Development, Inc.
Advanced Solid Tumors
United States, China, France, Japan, Puerto Rico +1 more

Previous page Next page